[{"from": "human", "value": "Could you provide a description of this molecule? [C][O][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C][=C][Branch1][Branch1][C][Ring1][=Branch1][=O][C][=C][C][=C][Ring1][Branch2][C][=Branch1][C][=O][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][C][N][C][C][C][=C][C][=Branch1][=N][=C][Branch1][Branch2][C][=C][Ring1][=Branch1][C][Ring1][#Branch2][O][C][O][C]"}, {"from": "gpt", "value": "The molecule is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued."}]